High Risk Clones

High Risk Clones

Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey.

By fernando | 29 Aug, 19 | 0 Comments |

Del Barrio-Tofiño E1, Sánchez-Diener I1, Zamorano L1, Cortes-Lara S1, López-Causapé…

O-antigen serotyping and MALDI-TOF, potentially useful tools for optimizing semi-empiric antipseudomonal treatments through the early detection of high-risk clones.

By fernando | 7 Feb, 19 | 0 Comments |

Mulet X1, García R1, Gayá M1, and Oliver A1 1Hospital…

@arpbigidisba

arpbigidisba @arpbigidisba ·

11 Jul

Notícia completa 👇🏻
https://diari.uib.es/Hemeroteca/Un-sistema-pionero-permite-predecir-la-resistencia.cid809294

Reply on Twitter 1943719646395293891 Retweet on Twitter 1943719646395293891 1 Like on Twitter 1943719646395293891 3 X 1943719646395293891

Retweet on Twitter arpbigidisba Retweeted

Docusalut @docusalut ·

10 Jul

Nou article a #Docusalut: 🦠🏥 Analysis of intrahospital and global dissemination and resistome dynamics of NDM-1-producing ST773 high-risk clone http://hdl.handle.net/20.500.13003/24750 @microHUSE @carla_lc2911 @aoliverp73 @idisbaib #PublicaSalutIB

Reply on Twitter 1943339897332363707 Retweet on Twitter 1943339897332363707 4 Like on Twitter 1943339897332363707 4 X 1943339897332363707

Retweet on Twitter arpbigidisba Retweeted

Infosalut @infosalut ·

7 Jul

#PublicaSalutIB @microHUSE i @idisbaib ha participat en la publicació d'un estudi sobre l'ús de la ceftazidima-avibactam indueix multiresistència i limita teràpies col·laterals contra P. aeruginosa https://www.infosalut.com/investigacio/estudis-i-projectes/17616 https://doi.org/10.1038/s41467-025-58597-6

@aoliverp73 @sonespases

Reply on Twitter 1942177351510503830 Retweet on Twitter 1942177351510503830 3 Like on Twitter 1942177351510503830 3 X 1942177351510503830

Retweet on Twitter arpbigidisba Retweeted

Docusalut @docusalut ·

1 Jul

Nou article a #Docusalut: 💊🦠 Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa http://hdl.handle.net/20.500.13003/24711 @microHUSE @sonespases @idisbaib #PublicaSalutIB

Reply on Twitter 1940040618232738063 Retweet on Twitter 1940040618232738063 3 Like on Twitter 1940040618232738063 2 X 1940040618232738063

arpbigidisba @arpbigidisba ·

2 Jul

The “2nd Hands On Workshop on Pseudomonas aeruginosa Resistance Phenotypes and Whole Genome Sequence Resistome Analysis” will begin in 2 months. This ESCMID workshop is organized by members of our group and will take place at the facilities of the Son Espases University Hospital.

Reply on Twitter 1940426817627918815 Retweet on Twitter 1940426817627918815 3 Like on Twitter 1940426817627918815 4 X 1940426817627918815

Retweet on Twitter arpbigidisba Retweeted

Docusalut @docusalut ·

27 Jun

Nou article a #Docusalut: 🦠 Pseudomonas aeruginosa chronic infections in patients with bronchiectasis: a silent reservoir of carbapenemase-producing epidemic high-risk clones http://hdl.handle.net/20.500.13003/24681 @carla_lc2911 @micro_huse @aoliverp73 #PublicaSalutIB

Reply on Twitter 1938515410179039479 Retweet on Twitter 1938515410179039479 1 Like on Twitter 1938515410179039479 2 X 1938515410179039479